Division of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e343-9. doi: 10.1016/j.ijrobp.2012.04.034. Epub 2012 Jun 1.
Vertebral compression fractures (VCFs) are increasingly observed after spine stereotactic body radiation therapy (SBRT). The aim of this study was to determine the risk of VCF after spine SBRT and identify clinical and dosimetric factors predictive for VCF. The analysis incorporated the recently described Spinal Instability Neoplastic Score (SINS) criteria.
The primary endpoint of this study was the development of a de novo VCF (ie, new endplate fracture or collapse deformity) or fracture progression based on an existing fracture at the site of treatment after SBRT. We retrospectively scored 167 spinal segments in 90 patients treated with spine SBRT according to each of the 6 SINS criteria. We also evaluated the presence of paraspinal extension, prior radiation, various dosimetric parameters including dose per fraction (≥20 Gy vs <20 Gy), age, and histology.
The median follow-up was 7.4 months. We identified 19 fractures (11%): 12 de novo fractures (63%) and 7 cases of fracture progression (37%). The mean time to fracture after SBRT was 3.3 months (range, 0.5-21.6 months). The 1-year fracture-free probability was 87.3%. Multivariate analysis confirmed that alignment (P=.0003), lytic lesions (P=.007), lung (P=.03) and hepatocellular (P<.0001) primary histologies, and dose per fraction of 20 Gy or greater (P=.004) were significant predictors of VCF.
The presence of kyphotic/scoliotic deformity and the presence of lytic tumor were the only predictive factors of VCF based on the original 6 SINS criteria. We also report that patients with lung and hepatocellular tumors and treatment with SBRT of 20 Gy or greater in a single fraction are at a higher risk of VCF.
脊柱立体定向体部放射治疗(SBRT)后,椎体压缩性骨折(VCF)的发生率越来越高。本研究旨在确定脊柱 SBRT 后 VCF 的风险,并确定预测 VCF 的临床和剂量学因素。分析中纳入了最近描述的脊柱不稳肿瘤评分(SINS)标准。
本研究的主要终点是在 SBRT 后治疗部位出现新的终板骨折或骨折进展(即新的骨折或现有骨折的塌陷变形)。我们回顾性地根据 SINS 的 6 项标准对 90 例接受脊柱 SBRT 治疗的 167 个脊柱节段进行评分。我们还评估了脊柱旁延伸、既往放疗、各种剂量学参数(包括每分次剂量[≥20 Gy 与<20 Gy])、年龄和组织学的存在。
中位随访时间为 7.4 个月。我们发现了 19 例骨折(11%):12 例新发骨折(63%)和 7 例骨折进展(37%)。SBRT 后骨折的平均时间为 3.3 个月(范围:0.5-21.6 个月)。1 年无骨折生存率为 87.3%。多变量分析证实,对线不良(P=.0003)、溶骨性病变(P=.007)、肺(P=.03)和肝细胞癌(P<.0001)原发组织学,以及 20 Gy 或更大的每分次剂量(P=.004)是 VCF 的显著预测因子。
根据最初的 6 项 SINS 标准,脊柱后凸/脊柱侧凸畸形的存在和溶骨性肿瘤的存在是 VCF 的唯一预测因素。我们还报告称,接受 SBRT 治疗且单次剂量为 20 Gy 或更大的肺和肝细胞癌患者发生 VCF 的风险更高。